

## From Evolution to Revolution: New Mechanisms of Action in Ulcerative Colitis

**NOV**

**5<sup>TH</sup>**

**2025** | 7:00pm CET

Sponsored by

**ABIVAX**

Recent advances in ulcerative colitis drug development have opened new therapeutic perspectives. This webinar brings together leading experts to discuss the latest phase 3 results with Obefazimod and explore future directions, including subgroup outcomes and combination therapy potential.

7:00 | 7:05pm

### **Welcome & Introduction 5'**

Bruce E. Sands (United States of America)

7:05 | 7:15pm

### **The Evolution of UC Drug Development 10'**

Raja Atreya (Germany)

7:15 | 7:30pm

### **A New Chapter: Phase 3 Induction Results with Obefazimod 15'**

Bruce E. Sands (United States of America)

7:30 | 7:50pm

### **Exploring Subgroup Outcomes and Potential for Combination Therapy 20'**

Silvio Danese (Italy)

7:50 | 8:00pm

### **Q&A 10'**

Raja Atreya (Germany)

Bruce E. Sands (United States of America)

Silvio Danese (Italy)

**CLICK HERE TO REGISTER**



**Silvio DANESE**

DIRECTOR, GASTROENTEROLOGY AND ENDOSCOPY  
IRCCS SAN RAFFAELE HOSPITAL, MILAN, ITALY  
PROFESSOR OF GASTROENTEROLOGY  
UNIVERSITY VITA-SALUTE SAN RAFFAELE, MILAN, ITALY



**Bruce E. SANDS**

PROFESSOR OF MEDICINE AND CHIEF,  
DR. HENRY D. JANOWITZ DIVISION OF  
GASTROENTEROLOGY, ICAHN SCHOOL OF  
MEDICINE AT MOUNT SINAI IN NEW YORK



**Raja ATREYA**

HEAD OF THE INFLAMMATORY BOWEL DISEASE (IBD)  
UNIT AND CLINICAL STUDY CENTRE OF THE UNIVERSITY  
HOSPITAL ERLANGEN, FRIEDRICH-ALEXANDER UNIVERSITY,  
ERLANGEN-NÜRNBERG, GERMANY

**ORGANIZATION OFFICE**



**Materia Prima**  
materia1a.it  
segreteria@materia1a.it